Helen Torley - Quest Diagnostics Independent Director
| DGX Stock | USD 151.92 0.96 0.64% |
Director
Dr. Helen I. Torley is Independent Director of the Company. Dr. Torley has, since 2014, been President and Chief Executive Officer of Halozyme Therapeutics, Inc., a biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals from August 2011 to December 2013, where she was responsible for the development of Onyxs commercial capabilities in the United States, Europe and Asia Pacific regions. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology business unit from 2003 to 2009 and the U.S. Bone Health business unit from 2009 to 2011. Prior to 2003, she held various senior management positions at BristolMyers Squibb and SandozNovartis, and was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley is a director of Halozyme Therapeutics, Inc., and she served as a director of Relypsa, Inc. from 2015 to 2016. Dr. Torley has extensive executive experience, including in general management, strategic planning and commercial operations, with multinational corporations operating in the healthcare industry. since 2018.
| Age | 58 |
| Tenure | 7 years |
| Address | 500 Plaza Drive, Secaucus, NJ, United States, 07094 |
| Phone | 973 520 2700 |
| Web | https://www.questdiagnostics.com |
Helen Torley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Helen Torley against Quest Diagnostics stock is an integral part of due diligence when investing in Quest Diagnostics. Helen Torley insider activity provides valuable insight into whether Quest Diagnostics is net buyers or sellers over its current business cycle. Note, Quest Diagnostics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Quest Diagnostics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Helen Torley over six months ago Disposition of 13092 shares by Helen Torley of Halozyme Therapeutics subject to Rule 16b-3 | ||
Helen Torley over a year ago Exercise or conversion by Helen Torley of 10000 shares of Halozyme Therapeutics subject to Rule 16b-3 | ||
Helen Torley over a year ago Exercise or conversion by Helen Torley of 10000 shares of Halozyme Therapeutics subject to Rule 16b-3 | ||
Helen Torley over a year ago Exercise or conversion by Helen Torley of 10000 shares of Halozyme Therapeutics subject to Rule 16b-3 |
Quest Diagnostics Management Efficiency
The company has Return on Asset of 0.0566 % which means that on every $100 spent on assets, it made $0.0566 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1322 %, implying that it generated $0.1322 on every 100 dollars invested. Quest Diagnostics' management efficiency ratios could be used to measure how well Quest Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.10 in 2025, whereas Return On Tangible Assets are likely to drop 0.14 in 2025. At this time, Quest Diagnostics' Other Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 7.66 in 2025, whereas Total Assets are likely to drop slightly above 8.5 B in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Nancy Andrews | Charles River Laboratories | 63 | |
| Elisha Finney | Mettler Toledo International | 59 | |
| George Scangos | Agilent Technologies | 72 | |
| Dow Wilson | Agilent Technologies | 61 | |
| Christopher Kuebler | Waters | 66 | |
| Stephen Chubb | Charles River Laboratories | 76 | |
| John Leonard | IQVIA Holdings | 62 | |
| Richard Wallman | Charles River Laboratories | 69 | |
| George Llado | Charles River Laboratories | 55 | |
| George Massaro | Charles River Laboratories | 73 | |
| WahHui Chu | Mettler Toledo International | 69 | |
| James Fasano | IQVIA Holdings | 50 | |
| Carol Burt | IQVIA Holdings | 62 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| John Connaughton | IQVIA Holdings | 54 | |
| Richard Francis | Mettler Toledo International | 52 | |
| Robert Bertolini | Charles River Laboratories | 59 | |
| Tadataka Yamada | Agilent Technologies | 74 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| Thomas Salice | Waters | 61 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0566 |
Quest Diagnostics Leadership Team
Elected by the shareholders, the Quest Diagnostics' board of directors comprises two types of representatives: Quest Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quest. The board's role is to monitor Quest Diagnostics' management team and ensure that shareholders' interests are well served. Quest Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quest Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Plewman, Senior Services | ||
| Garry Clark, Senior Officer | ||
| Gail Wilensky, Independent Director | ||
| Kristin Esq, Senior Officer | ||
| Stephen Rusckowski, CEO and President Director and Member of Executive Committee | ||
| Murali Balakumar, Chief VP | ||
| Wright Lassiter, Independent Director | ||
| Gary Pfeiffer, Independent Director | ||
| Vicky Gregg, Independent Director | ||
| Cecilia McKenney, Senior Officer | ||
| Helen Torley, Independent Director | ||
| Michael Prevoznik, Senior Vice President General Counsel | ||
| Tracey Doi, Independent Director | ||
| Karthik Kuppusamy, Senior Solutions | ||
| Catherine Doherty, Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing | ||
| Manuel Mendez, Senior Vice President Chief Commercial Officer | ||
| Gabrielle Wolfson, Senior Vice President and Chief Information and Digital Officer | ||
| Carrie Manner, Senior Vice President - Advanced Diagnostics | ||
| Sam Samad, Executive CFO | ||
| Dermot Shorten, MA Strategy | ||
| Shawn Bevec, Executive Director Investor Relations | ||
| Timothy Main, Independent Director | ||
| Michael Deppe, Vice President Corporate Controller and Chief Accounting Officer and Principal Accounting Officer | ||
| Mark Guinan, Chief Financial Officer, Executive Vice President | ||
| Daniel Stanzione, Non-Executive Chairman of the Board | ||
| Gary Samuels, Senior Officer | ||
| Michael JD, Senior Counsel | ||
| Denise Morrison, Independent Director | ||
| James Davis, Executive Vice President, General Diagnostics | ||
| Timothy Ring, Lead Independent Director |
Quest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quest Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0566 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 23.16 B | ||||
| Shares Outstanding | 111.61 M | ||||
| Shares Owned By Insiders | 0.40 % | ||||
| Shares Owned By Institutions | 91.55 % | ||||
| Number Of Shares Shorted | 1.91 M | ||||
| Price To Earning | 14.57 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Quest Stock Analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.